✦ LIBER ✦

5072 POSTER First-Line Bevacizumab (Bev) Combined With Paclitaxel (pac) in Older Patients (pts) Treated for HER2-Negative Metastatic Breast Cancer (mBC) in a Routine Oncology Practice Study

✍ Scribed by Foerster, F.; Aktas, B.; Geberth, M.; Tschechne, B.; Schneeweiss, A.; Salat, C.; Tesch, H.; Welslau, M.; Schmidt, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5073 POSTER Bevacizumab (Bev) Combined W

✍ Schneeweiss, A.; Foerster, F.; Hollburg, W.; Tesch, H.; Klare, P.; Wuelfing, P.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

1423 POSTER Polymorphism Analysis in the

✍ D.W. Miles; S.L. De Haas; G. Romieu; A. Chan; L. Dirix; J. Cortes; P.R. Delmar; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

5074 First-line bevacizumab (bev) plus p

✍ F. Foerster; M. Geberth; C. Schumacher; A. Schneeweiss; R. Weinberg; L. Hahn; M. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

470 Final results of a phase II study of

✍ S. Glück; C. Lobo; G. Lopes; A. Castrellon; J. Hurley; I. Reis; S. Richman; O. S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Motesanib, or open-label bevacizumab, in

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

Safety results from a phase III study (T

✍ I. Lang; M.J. Inbar; Z. Kahán; R. Greil; S. Beslija; S.M. Stemmer; B. Kaufman; Z 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 302 KB